Welcome to NEMORVEXA. These terms and conditions outline the rules and regulations for the use of our website.
By accessing this website, you accept these terms and conditions in full. Do not continue to use NEMORVEXA's website if you do not accept all of the terms and conditions stated on this page.
Unless otherwise stated, NEMORVEXA and/or its licensors own the intellectual property rights for all material on NEMORVEXA. All intellectual property rights are reserved. You may access this from NEMORVEXA for your own personal use subject to restrictions set in these terms and conditions.
Certain parts of this website offer the opportunity for users to post comments and exchange opinions and information. NEMORVEXA does not filter, edit, publish or review comments prior to their presence on the website. Comments do not reflect the views and opinions of NEMORVEXA, its agents or affiliates.
The following organizations may link to our website without prior written approval: government agencies, search engines, news organizations, online directory distributors.
Without prior approval and written permission, you may not create frames around our web pages that alter in any way the visual presentation or appearance of our website.
In no event shall NEMORVEXA, nor any of its officers, directors, and employees, be held liable for anything arising out of or in any way connected with your use of this website whether such liability is under contract. NEMORVEXA, including its officers, directors, and employees shall not be held liable for any indirect, consequential, or special liability arising out of or in any way related to your use of this website.
NEMORVEXA reserves the right to revise these terms at any time as it sees fit, and by using this website, you are expected to review these terms on a regular basis.
These terms will be governed by and interpreted in accordance with the laws of the country/state in which NEMORVEXA operates, and you submit to the jurisdiction of the courts located in that country/state for the resolution of any disputes.
Last updated on October 31, 2023